Valuation: BeOne Medicines AG

Capitalization 34.7B 29.45B 26.93B 25.46B 47.46B 3,278B 47.9B 319B 125B 1,573B 130B 127B 5,435B P/E ratio 2026 *
47.3x
P/E ratio 2027 * 32.8x
Enterprise value 30.94B 26.25B 24.01B 22.7B 42.31B 2,922B 42.7B 285B 111B 1,403B 116B 114B 4,845B EV / Sales 2026 *
4.79x
EV / Sales 2027 * 4.11x
Free-Float
0.74%
Yield 2026 *
-
Yield 2027 * -
1 day-1.54%
1 week+6.21%
Current month+5.71%
1 month-0.02%
3 months-11.81%
6 months-2.45%
Current year+2.74%
1 week 293.3
Extreme 293.3
318.06
1 month 289.54
Extreme 289.535
328.39
Current year 271.47
Extreme 271.4701
372.73
1 year 218.31
Extreme 218.31
385.22
3 years 126.97
Extreme 126.9681
385.22
5 years 118.18
Extreme 118.18
426.56
10 years 24.53
Extreme 24.53
426.56
Manager TitleAgeSince
Chief Executive Officer 57 28/10/2010
Director of Finance/CFO 50 22/07/2024
President 64 01/04/2018
Director TitleAgeSince
Chairman 57 27/01/2016
Director/Board Member 51 01/04/2015
Director/Board Member 52 01/10/2014
Change 5d. change 1-year change 3-years change Capi.($)
-1.54%+6.21%+32.29%+22.92% 34.7B
-0.66%+0.79%-15.44%-16.46% 43.39B
-0.49%+1.67%+238.37%+480.24% 30.15B
+0.04%+13.27%+16.58%-5.85% 29.83B
-2.02%-1.05%+29.45%+33.41% 28.46B
-6.96%+0.55%+424.83%+4,203.98% 14.48B
-3.04%+8.03% - - 14.74B
-0.41%+0.57%+131.18%+115.21% 12.51B
-0.64%+0.54%+5.74%-8.68% 12.29B
-1.10%+1.55%+40.95%+102.37% 12.11B
Average -1.68%+3.21%+100.44%+547.46% 23.27B
Weighted average by Cap. -1.40%+3.55%+79.52%+361.52%

Financials

2026 *2027 *
Net sales 6.46B 5.48B 5.02B 4.74B 8.84B 610B 8.92B 59.47B 23.21B 293B 24.24B 23.73B 1,012B 7.39B 6.27B 5.74B 5.42B 10.11B 698B 10.2B 68.04B 26.55B 335B 27.73B 27.15B 1,158B
Net income 744M 631M 577M 546M 1.02B 70.24B 1.03B 6.84B 2.67B 33.71B 2.79B 2.73B 116B 1.08B 914M 836M 790M 1.47B 102B 1.49B 9.91B 3.87B 48.82B 4.04B 3.95B 169B
Net Debt -3.76B -3.19B -2.92B -2.76B -5.15B -356B -5.2B -34.65B -13.52B -171B -14.12B -13.83B -590B -4.29B -3.64B -3.33B -3.15B -5.87B -406B -5.93B -39.52B -15.42B -195B -16.11B -15.77B -673B
Logo BeOne Medicines AG
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Employees
12,000
Date Price Change Volume
08/05/26 312.12 $ -1.54% 210,369
07/05/26 317.00 $ +1.17% 441,188
06/05/26 313.32 $ +5.32% 386,037
05/05/26 297.49 $ +0.12% 175,753
04/05/26 297.14 $ +1.12% 135,821
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
312.12USD
Average target price
411.27USD
Spread / Average Target
+31.77%

Quarterly revenue - Rate of surprise